Revolutionary Russian anti-cancer anti-PD1 medicine candidate has successfully ended pre-clinical animal trials, i.e. on primates. So far the product has demonstrated higher efficacy than the only two approved medicines acting against the same therapeutic target – pembrolizumab from Merck and nivolumab from BMS.
BIOCAD is now preparing for the first international multi-center clinical trials. Patients in Russia will be among the first to get access to the new generation therapy. The medicine is expected to be available to patients as early as in 2018 or 2019.